Standout Papers

The Pathogenesis of Rheumatoid Arthritis 2007 2026 2013 2019 4.0k
  1. The Pathogenesis of Rheumatoid Arthritis (2011)
    Iain B. McInnes, Georg Schett New England Journal of Medicine
  2. Rheumatoid arthritis (2016)
    Josef S Smolen, Daniel Aletaha et al. The Lancet
  3. Cytokines in the pathogenesis of rheumatoid arthritis (2007)
    Iain B. McInnes, Georg Schett Nature reviews. Immunology
  4. Rheumatoid arthritis (2018)
    Josef S Smolen, Daniel Aletaha et al. Nature Reviews Disease Primers
  5. The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention (2015)
    John J. O’Shea, Daniella M. Schwartz et al. Annual Review of Medicine
  6. Pathogenetic insights from the treatment of rheumatoid arthritis (2017)
    Iain B. McInnes, Georg Schett The Lancet
  7. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis (2009)
    M.J. Peters, Deborah Symmons et al. Annals of the Rheumatic Diseases
  8. Evidence that cytokines play a role in rheumatoid arthritis (2008)
    Fionula M. Brennan, Iain B. McInnes Journal of Clinical Investigation
  9. Disease-associated functions of IL-33: the new kid in the IL-1 family (2010)
    Foo Y. Liew, Nick Pitman et al. Nature reviews. Immunology
  10. Immunopathogenesis of Rheumatoid Arthritis (2017)
    Gary S. Firestein, Iain B. McInnes Immunity
  11. Explaining How “High-Grade” Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis (2003)
    Naveed Sattar, David McCarey et al. Circulation
  12. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2015)
    Iain B. McInnes, Philip J. Mease et al. The Lancet
  13. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial (2004)
    David McCarey, Iain B. McInnes et al. The Lancet
  14. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial (2013)
    Iain B. McInnes, Arthur Kavanaugh et al. The Lancet
  15. IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation (2009)
    Mariola Kurowska‐Stolarska, Bartosz Stolarski et al. The Journal of Immunology
  16. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis (2015)
    Philip J. Mease, Iain B. McInnes et al. New England Journal of Medicine
  17. IL-33 reduces the development of atherosclerosis (2008)
    Ashley M. Miller, Damo Xu et al. The Journal of Experimental Medicine
  18. A proinflammatory role for IL-18 in rheumatoid arthritis (1999)
    J. Alastair Gracie, Rosalyn Forsey et al. Journal of Clinical Investigation
  19. Interleukin-18 (2003)
    J. Alastair Gracie, Susan Robertson et al. Journal of Leukocyte Biology
  20. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial (2014)
    Christopher T. Ritchlin, Proton Rahman et al. Annals of the Rheumatic Diseases
  21. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study (2009)
    Arthur Kavanaugh, Iain B. McInnes et al. Arthritis & Rheumatism
  22. Obesity Is a Risk Factor for Severe COVID-19 Infection (2020)
    Naveed Sattar, Iain B. McInnes et al. Circulation
  23. Tendinopathy (2021)
    Neal L. Millar, Karin Grävare Silbernagel et al. Nature Reviews Disease Primers
  24. Cytokines in rheumatoid arthritis — shaping the immunological landscape (2015)
    Iain B. McInnes, Christopher D. Buckley et al. Nature Reviews Rheumatology
  25. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK (2023)
    Nathalie Conrad, Shivani Misra et al. The Lancet
  26. Inflammatory mechanisms in tendinopathy – towards translation (2017)
    Neal L. Millar, George A.C. Murrell et al. Nature Reviews Rheumatology
  27. Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases (2015)
    Stefan Siebert, Jamie Robertson et al. Pharmacological Reviews
  28. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial (2020)
    Philip J. Mease, Proton Rahman et al. The Lancet
  29. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs (2021)
    Georg Schett, Iain B. McInnes et al. New England Journal of Medicine
  30. The pathogenesis of rheumatoid arthritis (2022)
    Stefano Alivernini, Gary S. Firestein et al. Immunity
  31. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis (2020)
    Alexandre Sepriano, Andreas Kerschbaumer et al. Annals of the Rheumatic Diseases
  32. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis (2021)
    Iain B. McInnes, J. Anderson et al. New England Journal of Medicine
  33. Immune-mediated inflammatory disease therapeutics: past, present and future (2021)
    Iain B. McInnes, Ellen M. Gravallese Nature reviews. Immunology

Immediate Impact

11 by Nobel laureates 19 from Science/Nature 94 standout
Sub-graph 1 of 19

Citing Papers

GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases
2025 StandoutNature
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience

Works of Iain B. McInnes being referenced

Immune-mediated inflammatory disease therapeutics: past, present and future
2021 Standout
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
2015 Standout

Author Peers

Author Last Decade Papers Cites
Iain B. McInnes 23614 24776 10101 11889 721 56.6k
Marc Feldmann 15252 23651 5435 11157 554 52.9k
Georg Schett 21847 17536 5952 21051 1.1k 57.5k
Peter E. Lipsky 13513 22950 4478 8275 652 45.8k
T. Huizinga 27698 14454 6763 6397 1.1k 48.2k
Paul Emery 44932 17807 16957 5662 1000 65.3k
Yehuda Shoenfeld 22447 19589 8112 7868 1.6k 60.8k
Lars Klareskog 21624 13668 5046 5946 653 41.5k
Paul P. Tak 13649 11501 4318 8384 451 32.6k
Tadamitsu Kishimoto 8031 33603 8705 21971 633 76.3k
David Isenberg 27187 22345 4407 5885 950 44.7k

All Works

Loading papers...

Rankless by CCL
2026